The startling results of a recent study show that vaccine policy and evidence-based medicine are at odds with each other. The research looked into the effectiveness of the Human Papillomavirus (HPV) vaccine against cervical cancer, and found that the efficacy of HPV vaccines for this purpose has not been demonstrated. At the same time, the risks of the vaccines have yet to be fully evaluated.
This would seem to indicate that current worldwide HPV immunization practices are neither justified by long-term health benefits, nor economically viable. There is no evidence that HPV vaccination would reduce the rate of cervical cancer.
According to PR Web:
“Cumulatively, the list of serious adverse reactions related to HPV vaccination worldwide includes deaths, convulsions, paraesthesia, paralysis, Guillain-Barré syndrome (GBS), transverse myelitis, facial palsy, chronic fatigue syndrome, anaphylaxis, autoimmune disorders, deep vein thrombosis, pulmonary embolisms, and cervical cancers. Because the HPV vaccination program has global coverage, the long-term health of many women may be at risk against still unknown vaccine benefits.”